

# Joo Pedro Ferreira

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3498845/joao-pedro-ferreira-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

191  
papers

2,990  
citations

28  
h-index

45  
g-index

223  
ext. papers

5,392  
ext. citations

7.8  
avg, IF

5.74  
L-index

#	Paper	IF	Citations
191	A Randomized Controlled Trial of Renin-Angiotensin-Aldosterone System Inhibitor Management in Patients Admitted in Hospital with COVID-19.. <i>American Heart Journal</i> , <b>2022</b> , 247, 76-76	4.9	2
190	Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.. <i>European Journal of Heart Failure</i> , <b>2022</b> ,	12.3	4
189	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 135-141	6.7	6
188	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.. <i>Nature Medicine</i> , <b>2022</b> ,	50.5	27
187	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.. <i>Journal of the American College of Cardiology</i> , <b>2022</b> , 79, 1129-1137	15.1	1
186	Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort.. <i>Atherosclerosis</i> , <b>2022</b> , 346, 1-9	3.1	1
185	Effect of GLP-1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: a meta-analysis of placebo-controlled randomized trials.. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	1
184	Weak Association Between Genetic Markers of Hyperuricemia and Cardiorenal Outcomes: Insights From the STANISLAS Study Cohort With a 20-Year Follow-Up.. <i>Journal of the American Heart Association</i> , <b>2022</b> , e023301	6	
183	Response to the Letter to Editor: Methodological Issues with Meta-analysis.. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	
182	Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta-Analysis.. <i>Journal of the American Heart Association</i> , <b>2022</b> , 11, e024833	6	0
181	Differences in biomarkers and molecular pathways according to age for patients with HFrEF. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 2228-2236	9.9	3
180	Blood and Urine Biomarkers Predicting Worsening Kidney Function in Patients with Type 2 Diabetes Post-Acute Coronary Syndrome: An Analysis from the EXAMINE Trial. <i>American Journal of Nephrology</i> , <b>2021</b> , 1-8	4.6	0
179	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	26
178	Weight changes in heart failure with preserved ejection fraction: findings from TOPCAT. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	2
177	Circulating Biomarkers and Cardiac Structure and Function in Rheumatoid Arthritis. <i>Frontiers in Cardiovascular Medicine</i> , <b>2021</b> , 8, 754784	5.4	0
176	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2021</b> ,	18.1	3
175	Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	2

174	Outpatient diuretic intensification as endpoint in heart failure with preserved ejection fraction trials: an analysis from TOPCAT. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	1
173	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> ,	16.7	12
172	No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial. <i>Archives of Cardiovascular Diseases</i> , <b>2021</b> , 114, 814-817	2.7	1
171	Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2021</b> , 10, 127-131	4.3	1
170	The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart @MicsQn AGEing (HOMAGE) randomized clinical trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 684-696	9.5	23
169	Multi-proteomic approach to predict specific cardiovascular events in patients with diabetes and myocardial infarction: findings from the EXAMINE trial. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1006-1019	16.1	10
168	Plasma D-dimer concentrations predicting stroke risk and rivaroxaban benefit in patients with heart failure and sinus rhythm: an analysis from the COMMANDER-HF trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 648-656	12.3	5
167	Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 826-834	12.3	23
166	Impact of Geographic Region on the COMMANDER-HF Trial. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 201-211	7.9	4
165	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1397-1407	15.1	32
164	Heart failure re-hospitalizations and subsequent fatal events in coronary artery disease: insights from COMMANDER-HF, EPHEBUS, and EXAMINE. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1554-1563	6.1	4
163	Red cell distribution width in patients with diabetes and myocardial infarction: An analysis from the EXAMINE trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1580-1587	6.7	5
162	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , <b>2021</b> , 143, 949-958	16.7	2
161	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 1381-1392	15.1	30
160	Serum sodium and eplerenone use in patients with a myocardial infarction and left ventricular dysfunction or heart failure: insights from the EPHEBUS trial. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	0
159	Influence of sex, age and race on coronary and heart failure events in patients with diabetes and post-acute coronary syndrome. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 110, 1612-1624	6.1	3
158	Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 567-577	12.3	3
157	Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 665-674	3.3	1

156	Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	6.4	1
155	Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 268-277	7.9	13
154	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 780-788	3.3	1
153	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 1522-1545	1.9	7
152	Sodium-glucose co-transporter inhibitors in insulin-treated diabetes: a meta-analysis. <i>European Journal of Endocrinology</i> , <b>2021</b> , 184, 783-790	6.5	0
151	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , <b>2021</b> , 14, e008075	7.6	2
150	Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1477-1484	12.3	1
149	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4442-4451	9.5	6
148	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1529-1538	12.3	7
147	Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction. <i>International Journal of Cardiology</i> , <b>2021</b> , 332, 35-37	3.2	2
146	Identification of sex-specific biomarkers predicting new-onset heart failure. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 3512-3520	3.7	1
145	New-onset atrial fibrillation in patients with worsening heart failure and coronary artery disease: an analysis from the COMMANDER-HF trial. <i>Clinical Research in Cardiology</i> , <b>2021</b> , 1	6.1	2
144	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 1298-1305	16.2	2
143	Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. <i>European Journal of Internal Medicine</i> , <b>2021</b> , 85, 41-49	3.9	3
142	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 326-336	16.7	74
141	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. <i>Circulation</i> , <b>2021</b> , 143, 310-321	16.7	55
140	Subclinical ventricular dysfunction in rheumatoid arthritis. <i>International Journal of Cardiovascular Imaging</i> , <b>2021</b> , 37, 847-859	2.5	2
139	Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF) in patients in the ACCORD trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 782-790	6.7	3

138	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , <b>2021</b> , 143, 337-349	16.7	80
137	The Future of Meat: Health Impact Assessment with Randomized Evidence. <i>American Journal of Medicine</i> , <b>2021</b> , 134, 569-575	2.4	2
136	The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future. <i>American Journal of Medicine</i> , <b>2021</b> , 134, 166-175	2.4	7
135	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. <i>Heart Failure Reviews</i> , <b>2021</b> , 26, 11-21	5	1
134	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 671-680	9.5	36
133	Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF. <i>JACC: Heart Failure</i> , <b>2021</b> , 9, 13-24	7.9	10
132	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 1203-1212	9.5	34
131	Why are mineralocorticoid receptor antagonists the Cinderella in evidence-based treatment of myocardial infarction complicated with heart failure? Lessons from PARADISE-MI. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	3
130	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , <b>2021</b> ,	9.5	3
129	Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID-19): A structured summary of a study protocol for a randomized controlled trial. <i>Trials</i> , <b>2021</b> , 22, 115	2.8	1
128	Impact of Anti-hypertensive Therapy in the Sexual Health of Men and Women: An Analysis From the SPRINT Trial. <i>American Journal of Hypertension</i> , <b>2021</b> , 34, 760-772	2.3	0
127	Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction. <i>ESC Heart Failure</i> , <b>2021</b> , 8, 1700-1705	3.7	5
126	Head-to-head comparison of clustering methods for heterogeneous data: a simulation-driven benchmark. <i>Scientific Reports</i> , <b>2021</b> , 11, 4202	4.9	8
125	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 776-784	12.3	3
124	Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020053	6	6
123	Proteomic mechanistic profile of patients with diabetes at risk of developing heart failure: insights from the HOMAGE trial. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 163	8.7	2
122	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , <b>2021</b> , 144, 1284-1294	16.7	30
121	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , <b>2021</b> , 42, 4455-4464	9.5	5

120	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , <b>2021</b> , 23, 1798-1799	12.3	4
119	Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: Implications for future trial design. <i>Diabetes and Metabolism</i> , <b>2021</b> , 48, 101281	5.4	0
118	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1321-1332	15.1	10
117	Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals. <i>JACC: Cardiovascular Imaging</i> , <b>2021</b> ,	8.4	2
116	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1337-1348	15.1	8
115	Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort. <i>Clinical Cardiology</i> , <b>2021</b> , 44, 1516-1525	3.3	1
114	Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 187	8.7	1
113	Reduced Diuretic Dose in Patients Treated With Eplerenone: Data From the EPHESUS Trial. <i>Circulation: Heart Failure</i> , <b>2020</b> , 13, e006597	7.6	8
112	Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. <i>American Journal of Hypertension</i> , <b>2020</b> , 33, 1092-1101	2.3	9
111	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1615-1624	12.3	9
110	Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial. <i>BMC Medicine</i> , <b>2020</b> , 18, 165	11.4	7
109	Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 75, 2836-2850	15.1	36
108	Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial: Insights From COMMANDER HF. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 359-368	7.9	7
107	PCSK9 Protein and rs562556 Polymorphism Are Associated With Arterial Plaques in Healthy Middle-Aged Population: The STANISLAS Cohort. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014758	6.7	9
106	Covariate adjusted reanalysis of the I-Preserve trial. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 1358-1365	5.1	5
105	Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 953-963	3.7	3
104	Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 1673-1683	9.5	17
103	Enhanced clinical phenotyping by mechanistic bioprofiling in heart failure with preserved ejection fraction: insights from the MEDIA-DHF study (The Metabolic Road to Diastolic Heart Failure). <i>Biomarkers</i> , <b>2020</b> , 25, 201-211	2.6	11

102	Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 834-844	12.3	13
101	Predictors of sudden cardiac death in high-risk patients following a myocardial infarction. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 848-855	12.3	9
100	Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1711-1723	12.3	22
99	Biomarkers in patients with heart failure and central sleep apnoea: findings from the SERVE-HF trial. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 503-511	3.7	6
98	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 967-977	6.1	3
97	The prevalence and importance of frailty in heart failure with reduced ejection fraction—an analysis of PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2123-2133	12.3	22
96	Correlation of laboratory haemoconcentration measures with filling pressures obtained via pulmonary arterial pressure sensors in ambulatory heart failure patients. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1907-1911	12.3	4
95	Spironolactone metabolite concentrations in decompensated heart failure: insights from the ATHENA-HF trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 1451-1461	12.3	6
94	Eplerenone prevents an increase in serum carboxy-terminal propeptide of procollagen type I after myocardial infarction complicated by left ventricular dysfunction and/or heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 901-903	12.3	5
93	Impact of Uric Acid on Hypertension Occurrence and Target Organ Damage: Insights From the STANISLAS Cohort With a 20-Year Follow-up. <i>American Journal of Hypertension</i> , <b>2020</b> , 33, 869-878	2.3	8
92	Longer Duration of Hypertension and MRI Microvascular Brain Alterations Are Associated with Lower Hippocampal Volumes in Older Individuals with Hypertension. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 227-235	4.3	12
91	Circulating plasma proteins and new-onset diabetes in a population-based study: proteomic and genomic insights from the STANISLAS cohort. <i>European Journal of Endocrinology</i> , <b>2020</b> , 183, 285-295	6.5	3
90	Use of the Win Ratio in Cardiovascular Trials. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 441-450	7.9	13
89	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet, The</i> , <b>2020</b> , 396, 121-128	4.0	133
88	Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 71, 62-69	3.9	6
87	Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 188-198	7.9	20
86	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e012797	6	12
85	Body fat phenotypes and treatment response to spironolactone in ambulatory patients with heart failure and preserved ejection fraction: a post-hoc analysis of the Aldo-DHF trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 559-561	12.3	

84	Bioprofiles and mechanistic pathways associated with Cheyne-Stokes respiration: insights from the SERVE-HF trial. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 881-891	6.1	4
83	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIostat-CHF study. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 81-89	12.3	10
82	Estimating the Lifetime Benefits of Treatments for Heart Failure. <i>JACC: Heart Failure</i> , <b>2020</b> , 8, 984-995	7.9	2
81	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 200	8.7	5
80	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2393-2398	12.3	9
79	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2383-2392	12.3	41
78	Hypokalemia is frequent and has prognostic implications in stable patients attending the emergency department. <i>PLoS ONE</i> , <b>2020</b> , 15, e0236934	3.7	2
77	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. <i>American Heart Journal</i> , <b>2020</b> , 229, 40-51	4.9	4
76	Sex differences in circulating proteins in heart failure with preserved ejection fraction. <i>Biology of Sex Differences</i> , <b>2020</b> , 11, 47	9.3	5
75	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , <b>2020</b> , 396, 819-829	40	355
74	Serum potassium in the PARADIGM-HF trial. <i>European Journal of Heart Failure</i> , <b>2020</b> , 22, 2056-2064	12.3	14
73	Plasma protein biomarkers and their association with mutually exclusive cardiovascular phenotypes: the FIBRO-TARGETS case-control analyses. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 22-33	6.1	11
72	Chest X-ray quantification of admission lung congestion as a prognostic factor in patients admitted for worsening heart failure from the ICALOR cohort study. <i>International Journal of Cardiology</i> , <b>2020</b> , 299, 192-198	3.2	8
71	Determinants of anti-fibrotic response to mineralocorticoid receptor antagonist therapy: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) and Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction with Heart Failure (EPIHUS2) trials. <i>Clinical Research in Cardiology</i> , <b>2020</b> , 109, 161-164	6.1	15
70	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 3593-3602	9.5	38
69	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. <i>Circulation: Heart Failure</i> , <b>2019</b> , 12, e005897	7.6	33
68	Estimated Long-Term Survival With Eplerenone. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2357-2359	15.1	5
67	Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. <i>European Heart Journal Supplements</i> , <b>2019</b> , 21, A55-A60	1.5	8



66	Mean BMI, visit-to-visit BMI variability and BMI changes during follow-up in patients with acute myocardial infarction with systolic dysfunction and/or heart failure: insights from the High-Risk Myocardial Infarction Initiative. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 1215-1225	6.1	10
65	Nondipping Pattern and Cardiovascular and Renal Damage in a Population-Based Study (The STANISLAS Cohort Study). <i>American Journal of Hypertension</i> , <b>2019</b> , 32, 620-628	2.3	12
64	Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. <i>International Journal of Cardiology</i> , <b>2019</b> , 289, 91-98	3.2	13
63	Income Inequality and Outcomes in Heart Failure: A Global Between-Country Analysis. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 336-346	7.9	42
62	Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure. <i>Heart</i> , <b>2019</b> , 105, 307-314	5.1	18
61	Heart failure around the world. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 1187-1196	12.3	31
60	Eplerenone in patients with myocardial infarction and "mid-range" ejection fraction: An analysis from the EPHEBUS trial. <i>Clinical Cardiology</i> , <b>2019</b> , 42, 1106-1112	3.3	9
59	Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 386-388	12.3	21
58	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 345-351	12.3	28
57	Income level and inequality as complement to geographical differences in cardiovascular trials. <i>American Heart Journal</i> , <b>2019</b> , 218, 66-74	4.9	12
56	MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT. <i>JACC: Heart Failure</i> , <b>2019</b> , 7, 1012-1021	7.9	14
55	Heritability of a resting heart rate in a 20-year follow-up family cohort with GWAS data: Insights from the STANISLAS cohort. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 2047487319890763	3.9	3
54	Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 218-226	12.3	13
53	Echocardiographic diastolic function evolution in patients with an anterior Q-wave myocardial infarction: insights from the REVE-2 study. <i>ESC Heart Failure</i> , <b>2019</b> , 6, 70-79	3.7	2
52	Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 112-120	12.3	24
51	Prognostic value of estimated plasma volume in acute heart failure in three cohort studies. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 549-561	6.1	28
50	Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. <i>Clinical Research in Cardiology</i> , <b>2019</b> , 108, 477-486	6.1	39
49	Editor@ Choice- Impact of insulin-treated diabetes on cardiovascular outcomes following high-risk myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , <b>2019</b> , 8, 231-241	4.3	16

48	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , <b>2019</b> , 14, 197-214	2.9	33
47	Cohort Profile: Rationale and design of the fourth visit of the STANISLAS cohort: a familial longitudinal population-based cohort from the Nancy region of France. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 395-395j	7.8	21
46	Obesity and metabolic features associated with long-term developing diastolic dysfunction in an initially healthy population-based cohort. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 887-896	6.1	7
45	Relation of High Serum Bilirubin to Short-Term Mortality Following a Myocardial Infarction Complicated by Left Ventricular Systolic Dysfunction (from the High-Risk Myocardial Infarction Database Initiative). <i>American Journal of Cardiology</i> , <b>2018</b> , 121, 1015-1020	3	10
44	Interpretation of the ATHENA Trial-Caveats and Future Directions. <i>JAMA Cardiology</i> , <b>2018</b> , 3, 89-90	16.2	1
43	Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 727-735	15.1	18
42	Association between mean systolic and diastolic blood pressure throughout the follow-up and cardiovascular events in acute myocardial infarction patients with systolic dysfunction and/or heart failure: an analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 323-331	12.3	11
41	Practical management of concomitant acute heart failure and worsening renal function in the emergency department. <i>European Journal of Emergency Medicine</i> , <b>2018</b> , 25, 229-236	2.3	6
40	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. <i>ESC Heart Failure</i> , <b>2018</b> , 5, 139-148	3.7	14
39	Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 49-59	6.1	14
38	Individualizing treatment choices in the systolic blood pressure intervention trial. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 428-435	1.9	3
37	Data-Driven Approach to Identify Subgroups of Heart Failure With Reduced Ejection Fraction Patients With Different Prognoses and Aldosterone Antagonist Response Patterns. <i>Circulation: Heart Failure</i> , <b>2018</b> , 11, e004926	7.6	13
36	Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. <i>JACC: Heart Failure</i> , <b>2018</b> , 6, 813-822	7.9	20
35	NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). <i>Circulation</i> , <b>2018</b> , 137, 1671-1683	16.7	70
34	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , <b>2018</b> , 104, 606-613	5.1	9
33	Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial. <i>Clinical Research in Cardiology</i> , <b>2018</b> , 107, 1192-1195	6.1	4
32	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2018</b> , 11, e004783	5.8	7
31	Survival after bilateral internal mammary artery in coronary artery bypass grafting: Are women at risk?. <i>International Journal of Cardiology</i> , <b>2018</b> , 270, 89-95	3.2	4

30	Serum Chloride and Sodium Interplay in Patients With Acute Myocardial Infarction and Heart Failure With Reduced Ejection Fraction: An Analysis From the High-Risk Myocardial Infarction Database Initiative. <i>Circulation: Heart Failure</i> , <b>2017</b> , 10,	7.6	28
29	Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 974-986	12.3	23
28	Reply: Cardiopulmonary Exercise Testing Versus 6-Min Walk Test as Clinically Meaningful Endpoints in HF Trials. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 69, 2252	15.1	3
27	Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	27
26	High Pulse-Wave Velocity Defines a Very High Cardiovascular Risk Cohort of Dialysis Patients under Age 60. <i>American Journal of Nephrology</i> , <b>2017</b> , 45, 72-81	4.6	15
25	Lack of Diuretic Efficiency (but Not Low Diuresis) Early in An Acutely Decompensated Heart Failure Episode Is Associated with Increased 180-Day Mortality. <i>CardioRenal Medicine</i> , <b>2017</b> , 7, 137-149	2.8	8
24	Memory Alterations and White Matter Hyperintensities in Elderly Patients With Hypertension: The ADELAHYDE-2 Study. <i>Journal of the American Medical Directors Association</i> , <b>2017</b> , 18, 451.e13-451.e25	5.9	14
23	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure: BIOSTAT-CHF Subanalysis. <i>Journal of the American College of Cardiology</i> , <b>2017</b> , 70, 2128-2136	15.1	24
22	Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 271-279	12.3	22
21	Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2017</b> , 3, 48-57	6.4	48
20	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , <b>2017</b> , 19, 1284-1293	12.3	46
19	Intima-Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population-Based Cohort (STANISLAS Cohort Study). <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	44
18	Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. <i>European Heart Journal</i> , <b>2016</b> , 37, 2455-64	9.5	27
17	Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. <i>Clinical Research in Cardiology</i> , <b>2016</b> , 105, 489-507	6.1	26
16	Enlarging Red Blood Cell Distribution Width During Hospitalization Identifies a Very High-Risk Subset of Acutely Decompensated Heart Failure Patients and Adds Valuable Prognostic Information on Top of Hemoconcentration. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3307	1.8	11
15	Renal function estimation and Cockcroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart @Mics@n AGEing (HOMAGE) and the high-risk myocardial infarction database initiatives. <i>BMC Medicine</i> , <b>2016</b> , 14, 181	11.4	35
14	Natriuretic Peptides, 6-Min Walk Test, and Quality-of-Life Questionnaires as Clinically Meaningful Endpoints in HF Trials. <i>Journal of the American College of Cardiology</i> , <b>2016</b> , 68, 2690-2707	15.1	43
13	A tentative interpretation of the TOPCAT trial based on randomized evidence from the brain natriuretic peptide stratum analysis. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1411-1414	12.3	22

12	Heart failure and atrial fibrillation: from basic science to clinical practice. <i>International Journal of Molecular Sciences</i> , <b>2015</b> , 16, 3133-47	6.3	26
11	To the Editor--Diabetes and sudden death: Let's assess the absolute risk increase rather than the proportional risk from sudden cardiac death!. <i>Heart Rhythm</i> , <b>2015</b> , 12, e138	6.7	2
10	Geographic differences in heart failure trials. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 893-905	12.3	53
9	A Systematic Assessment of Absolute Treatment Effect. <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 829-31		2
8	Influence of spironolactone on matrix metalloproteinase-2 in acute decompensated heart failure. <i>Arquivos Brasileiros De Cardiologia</i> , <b>2015</b> , 104, 308-14	1.2	6
7	High-dose spironolactone changes renin and aldosterone levels in acutely decompensated heart failure. <i>Cor Et Vasa</i> , <b>2014</b> , 56, e463-e470	0.3	6
6	Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 67-72	3.9	57
5	High-sensitivity troponin T: a biomarker for diuretic response in decompensated heart failure patients. <i>Cardiology Research and Practice</i> , <b>2014</b> , 2014, 269604	1.9	7
4	The role of albuminuria as a non-invasive marker for congestive acutely decompensated chronic heart failure and the spironolactone effect in elderly Portuguese: a non-randomized trial. <i>Nephrology</i> , <b>2014</b> , 19, 149-56	2.2	2
3	Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. <i>Clinical Research in Cardiology</i> , <b>2013</b> , 102, 745-53	6.1	20
2	Left-sided infective endocarditis: analysis of in-hospital and medium-term outcome and predictors of mortality. <i>Revista Portuguesa De Cardiologia</i> , <b>2013</b> , 32, 777-84	1	18
1	Left-sided infective endocarditis: Analysis of in-hospital and medium-term outcome and predictors of mortality. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , <b>2013</b> , 32, 777-784	0	10